Special Research Initiatives - Grant ID: SR0354588
Funder
Australian Research Council
Funding Amount
$10,000.00
Summary
Integrated Nanoscale Biosystems Network (INBN). The INBN will integrate high-priority research, already identified by the ARC, in materials nanoscience and engineering with nanoscale biology. The INBN will provide the means to consolidate world-class multidisciplinary Australian research groups in existing Centres of Excellence, including several Federation Fellows, into a nanobiotechnology focus. The significant outcomes of INBN are the critical mass of outstanding researchers in the nanobiosci ....Integrated Nanoscale Biosystems Network (INBN). The INBN will integrate high-priority research, already identified by the ARC, in materials nanoscience and engineering with nanoscale biology. The INBN will provide the means to consolidate world-class multidisciplinary Australian research groups in existing Centres of Excellence, including several Federation Fellows, into a nanobiotechnology focus. The significant outcomes of INBN are the critical mass of outstanding researchers in the nanobiosciences, facilitation of innovative research to produce novel intellectual property and provision of pathways into collaborative research with international scientists and industry, and the training and development of the next generation scientists for this emerging discipline.
Read moreRead less
Exploiting the self-assembly of hydrophobin proteins to engineer functional nanostructuring surfaces. There is an increasing world-wide demand for advanced nano-biomaterials with novel properties. We will use natural hydrophobin proteins to coat nanodevices and make them more compatible with biological systems. Hydrophobin coatings will be applicable to biosensors, medical devices, diagnostics and drug delivery systems. The research will lead to an understanding of the basic mechanisms of protei ....Exploiting the self-assembly of hydrophobin proteins to engineer functional nanostructuring surfaces. There is an increasing world-wide demand for advanced nano-biomaterials with novel properties. We will use natural hydrophobin proteins to coat nanodevices and make them more compatible with biological systems. Hydrophobin coatings will be applicable to biosensors, medical devices, diagnostics and drug delivery systems. The research will lead to an understanding of the basic mechanisms of protein self-assembly and will have application outcomes that contribute to Australia being an important player in the field of nanotechnology. This is critical for Australia's long term competitiveness and productivity in and beyond the 21st century.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0560685
Funder
Australian Research Council
Funding Amount
$451,000.00
Summary
Scanning Probe Microscopy for Bioelectrochemistry. New methods to study the fundamental properties of biological samples, in particular proteins, are continuing to advance and impact on society. We will establish a leading edge facility for high-resolution imaging of biomolecules with redox functions. This will enable the continued development of new enzyme based diagnostic tests by understanding the dynamic nature of coupled electron and molecular interactions with redox enzymes in solution. Th ....Scanning Probe Microscopy for Bioelectrochemistry. New methods to study the fundamental properties of biological samples, in particular proteins, are continuing to advance and impact on society. We will establish a leading edge facility for high-resolution imaging of biomolecules with redox functions. This will enable the continued development of new enzyme based diagnostic tests by understanding the dynamic nature of coupled electron and molecular interactions with redox enzymes in solution. The bioelectrochemical imaging facility will be unique in Australia and establish an important cross-disciplinary approach within the international community.Read moreRead less
Special Research Initiatives - Grant ID: SR0354474
Funder
Australian Research Council
Funding Amount
$30,000.00
Summary
Metals in Medicine. Metal-based drugs account for several billion dollars of pharmaceutical sales worldwide, but proportionally much less research and development has focussed on this area than organic drugs. Australia has played a pivotal role in the early development of metal-based pharmaceuticals, which remains a research strength. The dual aims of the initiative are to provide a network for a vibrant industry based around metals in medicine and to improve the health of Australians. The ini ....Metals in Medicine. Metal-based drugs account for several billion dollars of pharmaceutical sales worldwide, but proportionally much less research and development has focussed on this area than organic drugs. Australia has played a pivotal role in the early development of metal-based pharmaceuticals, which remains a research strength. The dual aims of the initiative are to provide a network for a vibrant industry based around metals in medicine and to improve the health of Australians. The initiative will foster national and international cross-disciplinary collaborations to address the impediments holding back Australia's potential to take full advantage of our research strength in metals in medicine.Read moreRead less
Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in preg ....Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in pregnant women, and to further develop such antibodies for therapy. Identification of mothers at risk of FMAIT and the development of a specific therapy are vital to the management and prevention of this serious condition.Read moreRead less